Search This Blog

Thursday, April 30, 2026

Summit Therapeutics posts $189.4 million Q1 2026 net loss as ivonescimab Phase III spending rises

 

Summit Therapeutics posts $189.4 million Q1 2026 net loss as ivonescimab Phase III spending rises

  • Operating expenses rose sharply in Q1 2026 as Summit ramped ivonescimab Phase III development programs.
  • Interim PFS review for HARMONi-3 squamous cohort led independent data monitoring committee to recommend trial continue.
  • Committee reported no safety concerns and advised HARMONi-3 squamous cohort proceed as originally planned.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)